The distribution agreement covers the sale of AxiaLIF products in China with the exception of Hong Kong, Macau and Taiwan. TranS1’s AxiaLIF implants were granted a registration certificate by China’s State Food and Drug Administration, and the remaining instrumentation is expected to receive their respective registration in the fourth quarter of 2012.
More Articles on Orthopedic Devices:
Smith & Nephew Launches TRIGEN Low-Profile Screw
